RecruitingNCT06659458

Utilizing Long-read Sequencing to Investigate the EGFR Landscape of EGFR Positive Lung Cancer Patients

Sponsor

Our Lady of the Lake Hospital

Enrollment

20 participants

Start Date

Jan 1, 2025

Study Type

OBSERVATIONAL

Conditions

Lung Cancer (Non-Small Cell)EGFR Exon 19 Deletion Mutation

Summary

EGFR gene mutations are some of the most commonly occurring mutations in non-small cell lung cancer. Investigators have developed a DNA instability model that estimates a risk score to assess the likelihood of an individual acquiring a cancer-linked mutation. The aim of this study is to collect blood from both those diagnosed with EGFR positive lung cancer and healthy individuals, evaluate their gene sequence surrounding the EGFR landscape and use the cancer positive and healthy sequences to validate the risk assessment model, which may one day be used to provide insight on susceptibility of getting EGFR positive lung cancer or potentially other cancer types.

Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 100 Years

Plain Language Summary

Simplified for easier understanding

This study uses advanced DNA sequencing technology to study lung cancer tumors in women with EGFR-positive lung cancer — a specific genetic subtype. It also includes healthy women without cancer for comparison. The goal is to better understand how different EGFR mutations behave and how they may affect treatment. **You may be eligible if...** - You are a biological female between 18 and 100 years old - You have been diagnosed with EGFR-positive lung cancer (for the cancer group) - You are a healthy biological female with no cancer diagnosis (for the control group) **You may NOT be eligible if...** - You are under 18 years old - You are biologically male - You are currently incarcerated Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.